Alerts will be sent to your verified email
Verify Email
VISTAPH
|
Vista Pharma
|
Bacil Pharma
|
Lasa Supergenerics
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
-9.45 % | -73.86 % | -8.32 % |
|
5yr average Equity Multiplier
|
1.52 | 1.72 | 1.44 |
|
5yr Average Asset Turnover Ratio
|
0.14 | 0.0 | 0.77 |
|
5yr Avg Net Profit Margin
|
-199.64 % | 0.0 | -8.22 % |
|
Price to Book
|
1.34 | 2.44 | 0.69 |
|
P/E
|
0.0 | 55.58 | 0.0 |
|
5yr Avg Cash Conversion Cycle
|
397.29 Days | 0.0 | 11.27 Days |
|
Inventory Days
|
3019.63 Days | 0.0 | 46.83 Days |
|
Days Receivable
|
452.93 Days | 0.0 | 10.61 Days |
|
Days Payable
|
1804.78 Days | 23.71 Days | 83.41 Days |
|
5yr Average Interest Coverage Ratio
|
-2.3 | -950.16 | -18.91 |
|
5yr Avg ROCE
|
-7.56 % | -81.01 % | 1.03 % |
|
5yr Avg Operating Profit Margin
|
-188.68 % | 0.0 | 9.99 % |
|
5 yr average Debt to Equity
|
0.33 | 0.08 | 0.2 |
|
5yr CAGR Net Profit
|
4.15 % | -28.45 % | n/a |
|
5yr Average Return on Assets
|
-6.28 % | -72.13 % | -5.59 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
21.19 % | 0.2 % | 53.65 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 20.66 % |
|
Change in Promoter Holding (3 Yrs)
|
-14.25 % | -42.47 % | 9.87 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
-0.02 % | 0.0 | 0.0 |
|
Vista Pharma
|
Bacil Pharma
|
Lasa Supergenerics
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
-
|